Ventana Medical Systems, Inc., Tucson, AZ 85755, USA.
Methods. 2010 Dec;52(4):287-300. doi: 10.1016/j.ymeth.2010.08.012. Epub 2010 Aug 31.
With the advent of personalized medicine, anatomic pathology-based molecular assays, including in situ hybridization (ISH) and mRNA detection tests, are performed routinely in many laboratories and have increased in their clinical importance and complexity. These assays require appropriately fixed tissue samples that preserve both nucleic acid targets and histomorphology to ensure reliable test results for determining patient treatment options. However, all aspects of tissue processing, including time until tissue fixation, type of fixative, duration of fixation, post-fixation treatments, and sectioning of the sample, impact the staining results. ASCO/CAP has issued pre-analytical guidelines to standardize tissue processing for HER2 testing in breast carcinoma specimens: 10% neutral-buffered formalin (NBF) with a fixation time from at least 6 to 48h [1]. Often, this recommendation is not followed to the detriment of staining results [2]. In this paper, we used a human breast carcinoma cell line (MCF7) generated as xenograft tumors as a model system to analyze the effects of different pre-analytical conditions on ISH staining. We performed H&E, FISH and dual colorimetric HER2 ISH assays using specimens fixed across a range of times in six different commonly used fixatives. Additionally, we investigated the effects of varying tissue section thickness, which also impacted the quality of ISH staining. Finally, we evaluated the effects of three different decalcifying solutions on human breast specimens, typically a treatment that occurs post-fixation for evaluating metastases to bone. The results indicate that time and type of fixation treatment, as well as appropriate tissue thickness and post-fixation treatment, all contribute to the quality of ISH staining results. Our data support the ASCO/CAP recommendations for standardized tissue processing (at least 6h in formalin-based fixatives and 4μm section thickness) and indicate that certain fixatives and post-fixative treatments are detrimental to molecular staining results.
随着个性化医学的出现,基于解剖病理学的分子检测,包括原位杂交(ISH)和 mRNA 检测试验,在许多实验室中常规进行,并在其临床重要性和复杂性方面不断增加。这些检测需要适当固定的组织样本,既要保留核酸靶标,又要保留组织形态学,以确保检测结果可靠,从而确定患者的治疗选择。然而,组织处理的各个方面,包括组织固定的时间、固定剂的类型、固定的持续时间、固定后的处理以及样本的切片,都会影响染色结果。ASCO/CAP 发布了组织处理的分析前指南,以标准化乳腺癌标本 HER2 检测中的组织处理:10%中性缓冲福尔马林(NBF),固定时间至少为 6 至 48 小时[1]。通常,这种建议没有得到遵循,从而对染色结果产生不利影响[2]。在本文中,我们使用作为异种移植肿瘤生成的人乳腺癌细胞系(MCF7)作为模型系统,分析不同分析前条件对 ISH 染色的影响。我们使用固定在六种常用固定剂中的不同时间的标本进行 H&E、FISH 和双比色 HER2 ISH 检测。此外,我们研究了改变组织切片厚度的影响,这也会影响 ISH 染色的质量。最后,我们评估了三种不同脱钙溶液对人乳腺癌标本的影响,这种处理通常是在固定后用于评估转移到骨骼的情况。结果表明,固定时间和类型、适当的组织厚度和固定后处理,都会影响 ISH 染色结果的质量。我们的数据支持 ASCO/CAP 关于标准化组织处理的建议(福尔马林基固定剂中至少 6 小时和 4μm 切片厚度),并表明某些固定剂和固定后处理会对分子染色结果产生不利影响。